Executive Summary

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company based in San Diego, has filed its Annual Report on Form 10-K for the fiscal year ending December 31, 2025. The report contains significant updates regarding the company’s financial position, ongoing business strategy, risks, and forward-looking outlook. Investors and shareholders should take note of several critical factors that could impact Zentalis’ share price and overall value.

Key Points and Financial Highlights

• Limited Operating History & No Commercial Products: Zentalis remains a clinical-stage company with no products approved for commercial sale. This increases risk and uncertainty for investors regarding future revenues and profitability.
• Significant Net Losses: The company reported net losses of \$137.1 million in 2025 and \$165.9 million in 2024. As of December 31, 2025, Zentalis has an accumulated deficit of \$1.2 billion.
• Cash Position: Public float as of June 30, 2025, was approximately \$66.9 million, based on a closing price of \$1.16 per share. There were 70,931,016 shares outstanding as of March 20, 2026.
• Strategic Restructuring: In January 2025, Zentalis initiated a strategic restructuring effort including workforce reductions and cost-saving measures, aimed at extending its cash runway and focusing resources on key programs.
• Future Capital Needs: The company anticipates the need for additional capital to continue its operations and development programs and may pursue further financing, including at-the-market offerings.
• Pipeline & Partnerships: Zentalis is engaged in ongoing research and development of drug candidates (including azenosertib), with several collaborations and licensing agreements that may involve milestone and royalty payments.

Business and Strategic Developments

• Strategic Restructuring in January 2025:
  • The restructuring is expected to result in cost savings and extend the time the company can operate with its current cash resources.
  • Workforce reductions and reprioritization of development programs were announced, which may impact the speed and scope of R&D efforts but are aimed at focusing on the most promising assets.
• Pipeline Focus:
  • The company continues to advance its pipeline, including the development of azenosertib and other oncology candidates.
  • Future progress and market potential depend on clinical trial outcomes, regulatory approvals, and successful commercialization.
• Collaborative Agreements:
  • Expectations of milestone and royalty payments from partnerships, though the timing and amounts remain uncertain and are subject to clinical and regulatory milestones.
• Risks Related to Financial Health:
  • The company’s continued losses and lack of approved products mean that additional financings will be necessary and potentially dilutive to existing shareholders.

Risks and Shareholder Considerations

• Ongoing Losses and No Revenue: Zentalis expects to continue incurring significant net losses for the foreseeable future, with no guarantee of product approval or commercial revenue.
• Capital Requirements: The company’s cash position, while improved by cost-saving measures, is not expected to be sufficient to bring a product to market without additional financing.
• Dilution Risk: Further financing, including equity offerings, may dilute existing shareholders.
• Operational Risks: The company faces the risk of business interruptions, competition for talent, and macroeconomic uncertainties that could negatively impact operations and share value.
• Regulatory and Development Risks: All product candidates are subject to the risk of clinical trial failure, regulatory delays, or non-approval, which would significantly impact future prospects.
• Market Sensitivity: Any updates regarding clinical milestones, partnership payments, or additional restructuring may move the share price materially.

Summary for Investors

Zentalis Pharmaceuticals remains a high-risk, high-reward clinical-stage biotech. The company’s lack of commercialized products, ongoing significant net losses, and need for additional capital are critical considerations for current and prospective shareholders.

The strategic restructuring in January 2025 is a key development, as it reflects management’s focus on capital preservation and prioritization of core assets. While this may extend the company’s operational runway, it underscores the urgency for clinical and regulatory success or new financing.

Investors should closely monitor updates on clinical progress, partnership developments, and any further strategic changes, as these factors are likely to be highly price-sensitive and could significantly influence Zentalis’ market valuation.